Journal article
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study
Abstract
INTRODUCTION: FVIII inhibitor development is the most serious contemporary treatment complication in haemophilia A, particularly in previously untreated patients (PUPs). No inhibitors developed in clinical trials in previously treated patients treated with simoctocog alfa (Nuwiq), a fourth-generation recombinant FVIII produced in a human cell line.
METHODS: The NuProtect study investigated the immunogenicity of simoctocog alfa in PUPs. …
Authors
Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J
Journal
Thrombosis and Haemostasis, Vol. 121, No. 11, pp. 1400–1408
Publisher
Thieme
Publication Date
November 2021
DOI
10.1055/s-0040-1722623
ISSN
0340-6245